11 June, 2015

Skadden advised 3SBio, Inc. on its HKD 5.52bn (approximately USD 712m) public offering on the Hong Kong Stock Exchange. The listing was announced on 1 June and shares began trading on 11 June.  The Hong Kong public offer was more than 200 times oversubscribed.

Shenyang-based 3SBio, Inc. is a Chinese biotechnology company, producing pharmaceuticals to treat blood disorders and to counteract the side effects of chemotherapy. 

Skadden’s lead partners were Peter Huang, Christopher Betts and Will Cai.

Conventus Law